Kyverna Therapeutics Stock (NASDAQ:KYTX), Analyst Ratings, Price Targets, Predictions

The latest price target for Kyverna Therapeutics (NASDAQ: KYTX) was reported by JP Morgan on March 4, 2024. The analyst firm set a price target for $39.00 expecting KYTX to rise to within 12 months (a possible 145.75% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Kyverna Therapeutics (NASDAQ: KYTX) was provided by JP Morgan, and Kyverna Therapeutics initiated their overweight rating.

There is no last upgrade for Kyverna Therapeutics.

There is no last downgrade for Kyverna Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kyverna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kyverna Therapeutics was filed on March 4, 2024 so you should expect the next rating to be made available sometime around March 4, 2025.

While ratings are subjective and will change, the latest Kyverna Therapeutics (KYTX) rating was a initiated with a price target of $0.00 to $39.00. The current price Kyverna Therapeutics (KYTX) is trading at is $15.87, which is within the analyst’s predicted range.